Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2016

Open Access 01-12-2016 | Research

Reduced volume SIB-IMRT/IGRT to head and neck cancer in elderly and frail patients: outcome and toxicity

Authors: Christoph Straube, Steffi U. Pigorsch, Hagen Scherb, Jan J. Wilkens, Henning Bier, Stephanie E. Combs

Published in: Radiation Oncology | Issue 1/2016

Login to get access

Abstract

Background

Especially elderly and frail patients have a limited ability to compensate for side effects of a radical treatment of head and neck malignancies. Limiting the target volume to the macroscopic disease, without prophylactic nodal irradiation, might present a feasible approach for these patients. The present work therefore aims evaluating an IMRT/IGRT –SIB concept for safety and efficacy.

Methods

The study retrospectively enrolled 27 patients with head and neck cancers treated between 01/2012 and 05/2015. We evaluated patient files for clinical status, concomitant diseases, treatment side, and treatment volumes as well as for side effects and tumor responses. To describe efficacy and risk factors for worse outcome and higher grade toxicities, we performed cox regression analysis as well as Kaplan-Meier survival time analysis.

Results

Median survival was 181 days, 75 % patients showed an early local response at six weeks of follow up. Most patients developed mild to moderate acute toxicities, only one patient with grade IV mucositis was seen. The grade of toxicities was correlated to the size of the PTV. Concomitant diseases, metastatic disease, and G3 Grading were indicators for worse prognosis.

Conclusion

The IMRT/IGRT SIB concept is a safe and feasible radiotherapy concept for patients not able or not willing to undergo radical treatment.
Literature
1.
Rl S, Kd M, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):21254.
2.
Robert-Koch-Institut &, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland 2011/2012. 2015. S. 74-77.
3.
Forastiere A a, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845–52. cited 2014 Sep 15].CrossRefPubMed
4.
Nguyen-Tan PF, Zhang Q, Ang KK, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: Long-term report of efficacy and toxicity. J Clin Oncol. 2014;32(34):3858–67.CrossRefPubMedPubMedCentral
5.
Budach V, Stromberger C, Poettgen C, et al. Hyperfractionated accelerated radiation therapy (hart) of 70.6 gy with concurrent 5-fu/mitomycin c is superior to hart of 77.6 gy alone in locally advanced head and neck cancer: Long-term results of the aro 95-06 randomized phase III trial. Int J Radiat Oncol Biol Phys. 2015;91(5):916–24. Elsevier Inc.CrossRefPubMed
6.
Massa E, Madeddu C, Astara G, et al. An attempt to correlate a “Multidimensional Geriatric Assessment” (MGA), treatment assignment and clinical outcome in elderly cancer patients: Results of a phase II open study. Crit Rev Oncol Hematol. 2008;66(1):75–83.CrossRefPubMed
7.
Lucente FE. Treatment of head-and-neck carcinoma with noncurative intent. Am J Otolaryngol. 1994;15(2):99–102.CrossRefPubMed
8.
Kowalski LP, Carvalho a L. Natural history of untreated head and neck cancer. Eur J Cancer. 2000;36(8):1032–7.CrossRefPubMed
9.
10.
Porceddu SV, Rosser B, Burmeister BH, et al. Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment - “Hypo Trial”. Radiother Oncol. 2007;85(3):456–62.CrossRefPubMed
11.
Corry J, Peters LJ, D’Costa I, et al. The “QUAD SHOT” - A phase II study of palliative radiotherapy for incurable head and neck cancer. Radiother Oncol. 2005;77(2):137–42.CrossRefPubMed
12.
Mohanti BK, Umapathy H, Bahadur S, et al. Short course palliative radiotherapy of 20 Gy in 5 fractions for advanced and incurable head and neck cancer: AIIMS study. Radiother Oncol. 2004;71(3):275–80.CrossRefPubMed
13.
van Beek KM, Kaanders JHAM, Janssens GO, et al. Effectiveness and toxicity of hypofractionated high-dose intensity-modulated radiotherapy versus 2- and 3-dimensional radiotherapy in incurable head and neck cancer. Head Neck. 2015;55(7):E1264–E1270.
14.
Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27(2):131–46.CrossRefPubMed
15.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. Elsevier Ltd.CrossRefPubMed
16.
Monnier L, Touboul E, Durdux C, et al. Hypofractionated palliative radiotherapy for advanced head and neck cancer: The IHF2SQ regimen. Head Neck. 2013;35(12):1683–8.CrossRefPubMed
17.
Schilstra C, Meertens H. Palliative radiotherapy in recurrent head-and-neck tumors by a percutaneous superfractionated treatment schedule. Int J Radiat Oncol Biol Phys. 2001;50(1):65–8.CrossRef
18.
Lok BH, Jiang G, Gutiontov S, et al. Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. Oral Oncol. 2015;51(10):957–62. cited 2015 Aug 25.CrossRefPubMedPubMedCentral
19.
Agarwal JP, Nemade B, Murthy V, et al. Hypofractionated, palliative radiotherapy for advanced head and neck cancer. Radiother Oncol. 2008;89(1):51–6. Elsevier Ireland Ltd.CrossRefPubMed
20.
Tortochaux J, Tao Y, Tournay E, et al. Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent. Radiother Oncol. 2011;100(1):70–5. Elsevier Ireland Ltd.CrossRefPubMed
21.
Simeoni R, Breitenstein K, Eßer D, et al. Cardiac comorbidity in head and neck cancer patients and its influence on cancer treatment selection and mortality: a prospective cohort study. Eur Arch Otorhinolaryngol. 2016;273(9):2765–2772.
22.
Boje CR. Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma - A systematic review. Radiother Oncol. 2014;110(1):81–90.CrossRefPubMed
23.
Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA: Cancer J Clin. 2016;66(4):337–350.
24.
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;368(8):733–42.CrossRef
25.
Nakayama M, Tabuchi K, Hara A. Clinical utility of the modified Glasgow prognostic score in patients with advanced head and neck cancer. Head Neck. 2014;55(7):1745–1749.
26.
Naumann P, Habermehl D, Welzel T, et al. Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer. Strahlenther Onkol. 2013;189(9):745–52.CrossRefPubMed
Metadata
Title
Reduced volume SIB-IMRT/IGRT to head and neck cancer in elderly and frail patients: outcome and toxicity
Authors
Christoph Straube
Steffi U. Pigorsch
Hagen Scherb
Jan J. Wilkens
Henning Bier
Stephanie E. Combs
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2016
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-016-0711-x

Other articles of this Issue 1/2016

Radiation Oncology 1/2016 Go to the issue

Research

Adjuvant chemoradiotherapy instead of revision radical resection after local excision for high-risk early rectal cancer

Review

Target delineation and optimal radiosurgical dose for pituitary tumors

Review

A practical review of magnetic resonance imaging for the evaluation and management of cervical cancer

Research

High-risk factors of parotid lymph node metastasis in nasopharyngeal carcinoma: a case-control study

Research

Repeated iodine-125 seed implantations combined with external beam radiotherapy for the treatment of locally recurrent or metastatic stage III/IV non-small cell lung cancer: a retrospective study

Research

Impact of hypofractionation and tangential beam IMRT on the acute skin reaction in adjuvant breast cancer radiotherapy